[HTML][HTML] A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma

…, L Xiang, Y Yang, M Yang, D Wang, Y Li, R Xing… - Nature …, 2022 - nature.com
Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral skin, and has
a higher incidence in East Asians. We perform single-cell RNA sequencing for 63,394 cells …

[HTML][HTML] Apatinib as targeted therapy for sarcoma

F Li, Z Liao, C Zhang, J Zhao, R Xing, S Teng… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Sarcomas are a group of malignant tumors originating from mesenchymal tissue with a variety
of cell subtypes. Despite several major treatment breakthroughs, standard treatment using …

[HTML][HTML] Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

…, X Liu, T Li, P Xing, J Zhao, J Zhang, R Xing… - … & Molecular Medicine, 2019 - nature.com
Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth
factor receptor 2 (VEGFR-2). We conducted a single-arm, nonrandomized phase II study (…

[HTML][HTML] Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China

…, L Zhu, B Yang, X Bai, P Xing, J Zhang, R Xing… - Scientific Reports, 2019 - nature.com
Extraskeletal osteosarcoma (ESOS) is an extremely rare malignancy with poor prognosis,
accounting for 2–4% of all osteogenic sarcomas. The purpose of this study was to examine the …

[HTML][HTML] Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting

…, Y Xu, Y Chen, T Li, X Zhang, T Hu, R Xing… - Cancer Biology & …, 2022 - ncbi.nlm.nih.gov
At the recent 2022 American Society of Clinical Oncology (ASCO) annual meeting, the latest
progress was presented in clinical trials of various therapeutic modalities for adult soft tissue …

[HTML][HTML] Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846

…, L Zhu, Y Shi, G Zhao, X Bai, J Zhao, R Xing… - Biomedicine & …, 2020 - Elsevier
Background There is no standard treatment for stage IV soft tissue sarcoma (STS) after the
failure of Adriamycin-based chemotherapy. This phase II study (NCT03121846) assessed the …

[HTML][HTML] Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy

Z Liao, T Li, C Zhang, X Liu, R Xing, S Teng… - Cancer Biology & …, 2020 - ncbi.nlm.nih.gov
Objective: To analyze the efficacy and safety of apatinib in the treatment of stage IV osteogenic
sarcoma after chemotherapy failure through a single-arm, prospective, and open clinical …

[HTML][HTML] The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma

…, Y Zhao, H Wu, Z Ren, J Zhao, R Xing… - Cancer biology & …, 2022 - ncbi.nlm.nih.gov
Objective: Sarcomas are a group of rare malignancies with various subtypes. Patients with
metastatic sarcoma who have failed traditional treatments can possibly achieve better …

[HTML][HTML] Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV

P Xing, J Zhang, Z Yan, G Zhao, X Li, G Wang, Y Yang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Purpose This retrospective case-series study evaluated efficacy and safety of Endostar
combined with chemotherapy in the treatment of advanced bone and soft tissue sarcomas in …

[HTML][HTML] Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study

…, J Teng, T Li, H Liu, T Li, C Zhang, R Xing… - Frontiers in …, 2024 - frontiersin.org
Background Sarcoma is a highly heterogeneous malignancy with a poor prognosis. Although
chemotherapy and targeted therapy have improved the prognosis to some extent, the …